1. Home
  2. LITB vs LITS Comparison

LITB vs LITS Comparison

Compare LITB & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LightInTheBox Holding Co. Ltd.

LITB

LightInTheBox Holding Co. Ltd.

N/A

Current Price

$2.68

Market Cap

48.4M

ML Signal

N/A

LITS

Lite Strategy Inc.

N/A

Current Price

$1.11

Market Cap

40.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LITB
LITS
Founded
2007
2000
Country
Singapore
United States
Employees
N/A
4
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.4M
40.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
LITB
LITS
Price
$2.68
$1.11
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
8.0K
386.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.95
52 Week High
$4.17
$3.03

Technical Indicators

Market Signals
Indicator
LITB
LITS
Relative Strength Index (RSI) 46.62 44.79
Support Level $2.39 $0.95
Resistance Level $2.98 $1.16
Average True Range (ATR) 0.21 0.08
MACD -0.02 0.02
Stochastic Oscillator 13.46 57.45

Price Performance

Historical Comparison
LITB
LITS

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: